Dainippon Sumitomo To Launch Diabetes Drug Surepost
This article was originally published in PharmAsia News
Executive Summary
Dainippon Sumitomo Pharma will launch rapid-acting insulin Surepost (repaglinide) in Japan May 16. The insulin is the third in its class in Japan, after Fastic (nateglinide) from Ajinomoto/Astellas Pharma Inc., and Glufast (mitiglinide) from Kissei Pharmaceutical. (Click here for more - Japanese language